All-Amgen Denosumab Raises Hopes; Proof-Of-Concept Peek Due At ASCO
Executive Summary
If Amgen's denosumab works as well in Phase III as investors hope, the bone-building drug could become not only a bottom-line savior after the much-publicized trouble with erythropoietin stimulating agents, but could also become a matter of significant pride for its developers